Oncotelic Therapeutics - 23 Year Stock Price History | OTLC

Historical daily share price chart and data for Oncotelic Therapeutics since 1993 adjusted for splits. The latest closing stock price for Oncotelic Therapeutics as of December 07, 2016 is 0.35.
  • The all-time high Oncotelic Therapeutics stock closing price was 9611.04 on September 04, 1997.
  • The Oncotelic Therapeutics 52-week high stock price is 0.00, which is -100% above the current share price.
  • The Oncotelic Therapeutics 52-week low stock price is 0.00, which is 100% below the current share price.
  • The average Oncotelic Therapeutics stock price for the last 52 weeks is NaN.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Oncotelic Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2016 0.6345 0.7450 0.8380 0.3499 0.3499 -53.95%
2015 1.3242 1.7000 1.9200 0.7450 0.7599 -52.80%
2014 2.4797 2.7900 4.2900 1.5450 1.6100 -36.11%
2013 3.1798 5.3000 5.3000 2.1100 2.5200 -52.90%
2012 9.0053 11.8848 15.8463 4.0816 5.3500 -54.98%
2011 26.8112 55.2221 67.2269 10.8043 11.8848 -78.48%
2010 156.0053 278.5114 316.9268 48.0192 55.2221 -79.82%
2009 294.2510 156.0624 571.4286 124.8499 273.7095 72.73%
2008 350.6256 581.0324 595.4382 144.0576 158.4634 -73.49%
2007 904.2629 1152.4610 1178.8715 516.2065 597.8391 -48.13%
2006 961.3120 989.1957 1370.9484 684.2737 1152.4610 20.91%
2005 1150.8222 1397.3589 1435.7743 897.9592 953.1813 -27.82%
2004 1694.9351 2048.0192 2643.4574 1027.6110 1320.5282 -32.18%
2003 1614.7411 266.5066 3315.7263 254.5018 1947.1789 672.38%
2002 398.8167 804.3217 825.9304 201.6807 252.1008 -65.80%
2001 1142.5086 1486.1945 1966.3866 468.1873 737.0948 -47.79%
2000 3094.3234 3603.8415 6247.2989 1277.3109 1411.7647 -62.40%
1999 2652.4705 2463.3854 4835.5342 1786.3145 3755.1020 45.35%
1998 2677.5663 4324.1297 4506.6026 1111.6447 2583.4334 -38.55%
1997 6923.2689 5495.7983 9611.0444 3723.8896 4204.0816 -25.55%
1996 5001.5219 2372.1489 7719.0876 2223.2893 5647.0588 121.26%
1995 1589.7978 1140.4562 2643.4574 1080.4322 2552.2209 123.79%
1994 1796.2328 1591.8367 2552.2209 1126.0504 1140.4562 -28.36%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.048B $0.002B
Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29